Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
Executive Summary
Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.
You may also be interested in...
Regeneron/Sanofi, Amgen PCSK9 Rivalry Continues, But Not In US Courts
The battle for PCSK9 inhibitor market share continues with Amgen’s Repatha outselling Praluent, but a now-ended patent dispute no longer threatens Regeneron’s ability to sell its product in the US.
Amgen Has Relatively Smooth Sailing In Q2 Despite COVID-19 Headwinds
Amgen reported a 6% year-over-year increase in second quarter sales despite pandemic-related declines for several drugs as newer product gains and Otezla righted a rocky ship.
Otezla Is Amgen’s Main Growth Driver As Net Drug Pricing Declines
Without the newly purchased drug, Amgen’s 2020 sales would be flat, but the company hopes to enhance its psoriasis market push with its combined offering of Otezla, Enbrel and biosimilars.
Need a specific report? 1000+ reports available
Buy Reports